Oncology (all articles)
Guideline | Reporting of surgically removed lymph nodes for breast tumors.
25 Oct, 2022 | 13:20h | UTC
Systematic Review | Mu‐opioid antagonists for opioid‐induced bowel dysfunction in palliative care and people with cancer.
25 Oct, 2022 | 13:13h | UTC
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
24 Oct, 2022 | 14:12h | UTC
RCT | Effect of peritoneal fixation on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy.
24 Oct, 2022 | 14:05h | UTCEffect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/EUplatinum/status/1581244249412341761
Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.
24 Oct, 2022 | 14:01h | UTCRandomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network
Commentary on Twitter
Phase II CheckPAC Trial in refractory #PancreaticCancer
✅ 37.2% of pts achieved clinical benefit after stereotactic #RadiationTherapy in combination w/ nivolumab and ipilimumab
⛔ PD-L1 score was not associated with benefitRead more: https://t.co/rxDnYvIUMl #JCO #PancSM pic.twitter.com/u7FfQEwN7a
— Journal of Clinical Oncology (@JCO_ASCO) May 9, 2022
Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.
24 Oct, 2022 | 14:00h | UTCNews Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press
Commentaries:
Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay
ASCO Guideline | Treatment of metastatic colorectal cancer.
20 Oct, 2022 | 12:32h | UTCTreatment of Metastatic Colorectal Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary: ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic CRC – ASCO Daily News
Commentary on Twitter
‼️ @ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer
Read in #JCO ➡️ https://t.co/CqWdEoSIjd #crcsm #mCRC pic.twitter.com/3N25Fl02v6
— Journal of Clinical Oncology (@JCO_ASCO) October 17, 2022
Cohort Study | Use of straighteners and other hair products and incident uterine cancer.
20 Oct, 2022 | 12:28h | UTCNews Release: Hair straightening chemicals associated with higher uterine cancer risk – NIH News Releases
Commentaries:
Hair-straightening chemical products linked to increased uterine cancer risk in new study – CNN
Hair straightening chemicals may increase women’s risk of uterine cancer, study finds – NPR
Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.
20 Oct, 2022 | 12:24h | UTCNews Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh
Commentary from the author on Twitter (thread – click for more)
A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath pic.twitter.com/hMJQ4OAUld
— Aatur Singhi, MD PhD (@PancPathologist) October 10, 2022
RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022
NCCN Guideline | Rectal cancer.
19 Oct, 2022 | 14:25h | UTC
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.
Post-trial follow-up | Nivolumab plus ipilimumab vs. chemotherapy as first-line treatment for metastatic non-small cell lung cancer.
19 Oct, 2022 | 14:17h | UTCFive-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 – Journal of Clinical Oncology (link to abstract – $ for full-text)
Original Study: #ESMO19 –Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer
Cluster RCT | Primary prophylaxis with CSFs fails to improve outcomes in patients at intermediate risk for febrile neutropenia.
18 Oct, 2022 | 12:58h | UTC
Post-trial follow-up | Metastasis-directed therapy vs. observation in oligometastatic prostate cancer.
18 Oct, 2022 | 12:47h | UTCCommentary: Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term – Cancer Therapy Advisor
Commentary on Twitter
🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
🎯 Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost https://t.co/OO8kcTVvFT pic.twitter.com/FqxGisz34F— Journal of Clinical Oncology (@JCO_ASCO) September 19, 2022
Isocitrate dehydrogenase mutant gliomas: consensus review on diagnosis, management, and future directions.
17 Oct, 2022 | 12:31h | UTC
Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
17 Oct, 2022 | 12:27h | UTCOriginal Study: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
OS from #OlympiA now out on Annals. After 3.5y of f-up, pts receiving adjuvant olaparib derived a significant OS benefit (4y Δ 3.4%, 89.8% vs 86.4%). No increased risk of MDS/AML with olaparib. Important to test for BRCA in potentially eligible patients.https://t.co/ygkr0cOwF0 pic.twitter.com/bg4Y2yyXwZ
— Paolo Tarantino (@PTarantinoMD) October 11, 2022
Images under a Creative Commons Attribution (CC BY 4.0) license
Single-arm phase 2 study | A less intensive treatment strategy may be effective for patients with stage IIA and stage IIB seminoma.
17 Oct, 2022 | 12:25h | UTCSingle-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: De-escalation Strategy in Seminoma: An Alternative Option? – Medscape (free registration required)
Commentary on Twitter
🚨🚨
SAKK 01/10 results are out!! 👇🏽Stage IIA/B testicular seminoma➡️
1️⃣cycle of carboplatin+involved node RT
116 pts, median FU 4.5yrs
3yr PFS 93.7%, 7 relapses, all successfully salvaged. Seminoma-specific surv 💯%
Generally well tolerated, gr3+tox chemo-related https://t.co/vI6ipafhZ8— Sophia Kamran, MD (@sophia_kamran) October 11, 2022
RCT | Adjuvant capecitabine following concurrent CTX-RT in locoregionally advanced nasopharyngeal carcinoma.
17 Oct, 2022 | 12:15h | UTC
Cohort Study | Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer.
17 Oct, 2022 | 12:14h | UTC
Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
14 Oct, 2022 | 14:12h | UTC
4-year follow-up of a RCT | Pembrolizumab with vs. without chemotherapy in recurrent or metastatic head and neck SCC.
14 Oct, 2022 | 14:11h | UTCOriginal Study: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.
14 Oct, 2022 | 14:03h | UTC
M-A | Incidence of cutaneous adverse events with Phosphoinositide 3-Kinase inhibitors as adjuvant therapy in patients with cancer.
14 Oct, 2022 | 14:01h | UTCIncidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)
15-year benefits of sigmoidoscopy screening on colorectal cancer incidence and mortality: a pooled analysis of randomized trials.
13 Oct, 2022 | 13:48h | UTC15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians
Related:
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Commentary on Twitter
A pooled analysis evaluating 15-yr effect of sigmoidoscopies found that receiving 1 #sigmoidoscopy significantly reduces long-term incidence of CRC in men and women: https://t.co/QXj5VRMHeo pic.twitter.com/s82sOJmBzr
— Annals of Int Med (@AnnalsofIM) October 11, 2022